Comparison Of Clinical Outcomes, Resource Utilisation, And Costs In Patients Hospitalized For ACS Managed With PCI And Receiving Prasugrel Or Ticagrelor (H7T-US-B019)

Study identification

• EU PAS number:
  EUPAS9938
• Study ID:
  9939
• Official title and acronym:
  Comparison Of Clinical Outcomes, Resource Utilisation, And Costs In Patients Hospitalized For ACS Managed With PCI And Receiving Prasugrel Or Ticagrelor (H7T-US-B019)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study is an observational retrospective database analysis designed to compare 30-day net adverse clinical event (NACE) rates in ACS patients who were managed with PCI. The major hypothesis of this studyis that, after adjustment for baseline differences, prasugrel will be non-inferior to ticagrelor through 30 days in ACS-PCI patients in regards to NACE.
• Study status:
  Finalised

Research institutions and networks

Institutions

IM Health Incorporated

Study timelines

Date when funding contract was signed

Planned:23/03/2013

Actual:23/03/2013

Study start date

Planned:15/10/2013

Actual:15/10/2013

Data analysis start date

Planned:17/10/2013

Actual:17/10/2013

Date of interim report, if expected

Planned:04/11/2013

Actual:04/11/2013

Date of final study report

Planned:10/02/2014

Actual:10/02/2014

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company, Daiichi Sankyo Inc

Regulatory

• Was the study required by a regulatory body?:
  No